Aadi Biosci 
Welcome,         Profile    Billing    Logout  
 1 Product   2 Diseases  1 Product   8 Trials   24 News 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci
NCT03463265: Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

Completed
2
62
US
nab-sirolimus, nab-sirolimus + temozolomide, temozolomide, nab-sirolimus + bevacizumab, bevacizumab, nab-sirolimus + lomustine, lomustine (CCNU), nab-sirolimus + marizomib (MRZ), marizomib (MRZ), nab-sirolimus + temozolomide + radiotherapy, radiation
Aadi Bioscience, Inc.
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
08/22
08/22
NARETO, NCT06494150: Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer

Not yet recruiting
2
37
US
nab-Sirolimus, Fyarro, Fulvestrant, Faslodex
University of Oklahoma, Aadi Bioscience, Inc.
Low Grade Ovarian Serous Adenocarcinoma
08/27
09/29
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
EEC-201, NCT05997017: Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

Recruiting
2
29
US
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial Cancer
03/25
10/26
NET-202, NCT05997056: Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Recruiting
2
21
US
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Tumor, Pulmonary Neuroendocrine Tumor
05/25
12/25
NCI-2018-01624, NCT03660930: Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Active, not recruiting
1/2
19
US
Sirolimus Albumin-bound Nanoparticles, Nab-Rapamycin, Nanoparticle Albumin-Bound Rapamycin, ABI-009, Nanoparticle Albumin-bound Sirolimus, Fyarro, Sirolimus Protein-bound Particles, Pazopanib hydrochloride, Votrient
University of Washington, Aadi Bioscience, Inc.
Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
11/22
02/25
NCT02975882: Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Active, not recruiting
1
33
US
Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, CPT11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U 101440E, U-101440E, U101440E, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus Albumin-bound Nanoparticles, ABI 009, ABI-009, ABI009, Albumin-bound Sirolimus, Fyarro, Nab-Rapamycin, Nab-sirolimus, Nanoparticle Albumin-Bound Rapamycin, Nanoparticle Albumin-bound Sirolimus, Sirolimus Albumin-bound Particles, Sirolimus Protein-bound Particles, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
Children's Oncology Group, National Cancer Institute (NCI)
Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm
03/22
09/25
RaSuRE, NCT03646240: ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy

Completed
1
14
US
ABI-009
Seattle Children's Hospital, Aadi Bioscience, Inc.
Epilepsy Intractable
08/22
12/22
NCT05661461: Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

Recruiting
1
28
US
nab-sirolimus, ABI-009, nab-rapamycin, albumin-bound rapamycin
Aadi Bioscience, Inc.
Tumor, Solid, Tumor, Advanced Solid Tumor
04/25
04/25
NCT06308419: A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

Recruiting
1
12
US
Gemcitabine, Gemcitabine Hydrochloride, Gemzar®, Nab-Sirolimus
M.D. Anderson Cancer Center, Aadi Bioscience
Leiomyosarcoma, Soft-tissue Sarcomas
02/29
02/31
KRYSTAL -19, NCT05840510: Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Active, not recruiting
1
79
US
Adagrasib, MRTX849, Krazati, nab-Sirolimus, ABI -009, Fyarro
Mirati Therapeutics Inc., Aadi Bioscience, Inc.
Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
12/25
06/26
GB004 / Aadi Biosci
No trials found
razuprotafib topical (AKB-9778 topical) / Aadi Biosci
No trials found
ARP-1536 / Aadi Biosci
No trials found
razuprotafib subcutaneous (AKB-9778 SC) / Aadi Biosci
No trials found

Download Options